SCHEMBL1608528

SCHEMBL1608528

Cc1cc(-c2nc(-c3cccc(O)c3)no2)cnc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 10/20 0.49
▸ RAB9A P51151 9/20 0.49
▸ SMN1; SMN2 Q16637 6/20 0.49
▸ TP53 P04637 5/20 0.49
▸ MAPT P10636 5/20 0.46
▸ POLB P06746 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ GRM5 P41594 1/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ NFKB1 P19838 2/20 0.41
▸ NFKB2 Q00653 2/20 0.41
▸ RELA Q04206 2/20 0.41
▸ PKM P14618 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ S1PR1 P21453 3/20 0.41
▸ TSHR P16473 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1251096 0.91 NPC1 (0.60) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL1250873 0.86 NPC1 (0.50) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL1608540 0.83 NPC1 (0.67) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL28664805 0.78 ADORA3 (0.52) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL12586868 0.78 HSD17B1 (0.55) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL2063496 0.76 NR1H4 (0.67) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL1249937 0.76 MAPT (0.60) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL12643444 0.75 NR1H4 (0.53) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL764971 0.73 L3MBTL1 (0.77) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL7958582 0.73 NR1H4 (0.67) NPC1RAB9ASMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 NPC1 129/4885RAB9A 4026/4885SMN1; SMN2 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback